https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:432 Thu 25 Jul 2013 09:10:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12375 Sat 24 Mar 2018 08:15:09 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17113 interaction <0.0001). At 30 days, the relative risk of mortality due to AF was 3.16 (95% CI 1.92–5.25) amongst those younger than 50, 1.71 (95% CI 1.32–2.22) in patients aged 50–64 years, 1.39 (95% CI 1.16–1.66) in patients aged 65–74 years, 1.29 (95% CI 1.17–1.43) in those aged 75–84 years, and 1.23 (95% CI 1.13–1.33) in those aged 85+ years. AF patients, surviving admission, spent a median of 19.2 days (95% CI 18.4–20.1) in hospital compared with 14.5 days (95% CI 13.9–15.1) for patients without AF (p < 0.001), with differences in length of stay greatest in younger patients (p value_interaction <0.0001). 90-Day stroke survivors with AF spent an average of 21.5 days (95% CI 20.6–22.4) in hospital versus 16.6 days (95% CI 15.9–17.2) in those without AF. AF patients accessed more in-hospital rehabilitation (36.6%; 95% CI 35.0–38.2) than patients without AF (31.8%; 95% CI 31.0–32.7) (p value <0.0001), and differences in the proportion of AF versus non-AF patients accessing rehabilitation was greatest in younger patients (p value_interaction <0.0006). Conclusions: Ischaemic stroke patients with AF have substantially worse outcomes than patients without AF, which can be partly explained by older age and greater co-morbidities. We have quantified the large effect of AF in younger patients and our results strongly argue for new antithrombotic research in young AF patients.]]> Sat 24 Mar 2018 08:02:27 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23069 Sat 24 Mar 2018 07:12:27 AEDT ]]>